11 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Targeted degradation of METTL3 against acute myeloid leukemia and gastric cancer.
Yonsei University College of Medicine
Discovery, Optimization, and Preclinical Pharmacology of EP652, a METTL3 Inhibitor with Efficacy in Liquid and Solid Tumor Models.
Epics Therapeutics SA
Virtual Screening and Molecular Docking: Discovering Novel METTL3 Inhibitors.
Hangzhou Medical College
Identification of an m6A Natural Inhibitor, Lobeline, That Reverses Lenvatinib Resistance in Hepatocellular Tumors.
The First Hospital of China Medical University
Small molecules that regulate the N6-methyladenosine RNA modification as potential anti-cancer agents.
University of Connecticut
Rational design of novel nucleoside analogues reveals potent antiviral agents for EV71.
Swansea University
METTL3 from Target Validation to the First Small-Molecule Inhibitors: A Medicinal Chemistry Journey.
Sapienza University of Rome
